02:27 PM EDT, 06/14/2024 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) shares fell 33% in recent Friday afternoon trading after the company released a data update on its lead chimeric antigen receptor, or CAR, T-cell therapy candidate, dubbed KYV-101.

The company presented the data at a conference. It said that early data from a group of 50 patients treated with CAR in KYV-101 showed "promising" outcomes across different indications in neurology, rheumatology, and hematology.

The therapy demonstrated CAR T-cell expansion, B-cell depletion, autoantibody reduction, disease impact, and durable immunomodulator-free response in a 30-patient cohort with autoimmune indications, the company said.

Price: 9.67, Change: -4.77, Percent Change: -33.03